RESUMO
As the burden of diabetes continues to grow and treatment standards require careful tracking of wound progress, clinicians increasingly need to rely on technological improvements in wound measurement technologies to track the progress of their treatments. This study aims to determine the accuracy of a new three-dimensional wound measurement (3DWM) device against laser-assisted wound measurement (LAWM) devices and traditional methods of wound measurement. Using several wound models, we demonstrate that the 3DWM device measures wound area, depth and volume similarly to the other methods tested. This is especially apparent when changes in wound measurements were compared between the two devices. Differences between the two technologies were apparent when analysing wound measurement time and measurement repeatability. There was a significantly lower incidence of error in measurements between the 3DWM device and the LAWM device. Finally, the measurement time was significantly faster with the 3DWM device compared to the LAWM device. Together, these data demonstrate that the 3DWM device provides an accurate and reproducible method for measuring changes in wound healing similar to other available technologies. Further, the use of the 3DWM device provides a faster and more consistent measurement, which is critical for clinical application and use.
Assuntos
Precisão da Medição Dimensional , Imageamento Tridimensional/instrumentação , Cicatrização/fisiologia , Ferimentos e Lesões/diagnóstico por imagem , Análise de Variância , Humanos , Lasers , Modelos Anatômicos , Projetos PilotoAssuntos
Antibacterianos/uso terapêutico , Bandagens , Desbridamento , Pé Diabético/terapia , Tratamento de Ferimentos com Pressão Negativa , Tendão do Calcâneo , Pé Diabético/diagnóstico , Pé Diabético/epidemiologia , Neuropatias Diabéticas/diagnóstico , Neuropatias Diabéticas/epidemiologia , Gerenciamento Clínico , Humanos , Fator de Crescimento Derivado de Plaquetas/uso terapêutico , Plasma Rico em Plaquetas , Fatores de Risco , Sapatos , Sociedades Médicas , Procedimentos Cirúrgicos Vasculares , Suporte de CargaRESUMO
OBJECTIVE: To review the efficacy and safety of fesoterodine, a new antimuscarinic for treating overactive bladder (OAB) symptoms. METHODS: Review of efficacy and safety data from the pivotal phase 3 trials of fesoterodine for the treatment of OAB. Although there were a number of additional end points, they were not included in the US prescribing information for fesoterodine and thus are not included in this article. RESULTS: OAB is a chronic condition affecting both men and women. The principal symptom is urgency, with or without urgency incontinence, with some patients experiencing increased daytime frequency and nocturia. In two 12-week, randomized, double-blind, phase 3 trials, fesoterodine 4 and 8 mg administered once daily were significantly better than placebo in alleviating OAB symptoms, as determined by changes in bladder diary variables. Both doses of fesoterodine were well tolerated. CONCLUSIONS: Fesoterodine is an efficacious, well-tolerated treatment for OAB.